title: Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
abstract: Gemcitabine is one of the most widely used drugs for the treatment of advanced Non-small cell lung cancer (NSCLC), but modest objective response rate of patients to gemcitabine makes it necessary to identify novel biomarkers for patients who can benefit from gemcitabine-based therapy and to improve the effect of clinical therapy. In this work, 3 NSCLC cell lines displaying different sensitivities to gemcitabine were applied for mRNA and microRNA (miR) expression chips to figure out the biomarkers for gemcitabine sensitivity. Genes whose expression increased dramatically in sensitive cell lines were mainly enriched in cell adhesion (NRP2, CXCR3, CDK5R1, IL32 and CDH2) and secretory granule (SLC11A1, GP5, CD36 and IGF1), while genes with significantly upregulated expression in resistant cell line were mainly clustered in methylation modification (HIST1H2BF, RAB23 and TP53) and oxidoreductase (TP53I3, CYP27B1 and SOD3). The most intriguing is the activation of Wnt/β-catenin signaling in gemcitabine resistant NSCLC cell lines. The miR-155, miR-10a, miR-30a, miR-24-2* and miR-30c-2* were upregulated in sensitive cell lines, while expression of miR-200c, miR-203, miR-885-5p, miR-195 and miR-25* was increased in resistant cell line. Genes with significantly altered expression and putatively mediated by the expression-changed miRs were mainly enriched in chromatin assembly (MAF, HLF, BCL2, and IGSF3), anti-apoptosis (BCL2, IGF1 and IKBKB), protein kinase (NRP2, PAK7 and CDK5R1) (all the above genes were upregulated in sensitive cells) and small GTPase mediated signal transduction (GNA13, RAP2A, ARHGAP5 and RAB23, down-regulated in sensitive cells). Our results might provide potential biomarkers for gemcitabine sensitivity prediction and putative targets to overcome gemcitabine resistance in NSCLC patients.
authors.affiliation: Department of rheumatism and immunology, First Clinical Medical College affiliated to Harbin Medical University Harbin, China.
authors.forename: Hai-Hong
authors.initials: HH
authors.lastname: Zhang
authors.forename: Zhi-Yi
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Chun-Li
authors.initials: CL
authors.lastname: Che
authors.forename: Yi-Fang
authors.initials: YF
authors.lastname: Mei
authors.forename: Yu-Zhi
authors.initials: YZ
authors.lastname: Shi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004354:Drug Screening Assays, Antitumor; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D053263:Gene Regulatory Networks / Q000187:drug effects; D005838:Genotype; D006801:Humans; D020128:Inhibitory Concentration 50; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D018579:Patient Selection; D010641:Phenotype; D012333:RNA, Messenger / Q000378:metabolism; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D035683:MicroRNAs; D012333:RNA, Messenger; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Non-small cell lung cancer; gemcitabine; gene expression profiles; miR expression profiles
references.citation: PLoS One. 2012;7(12):e52310
references.pmid: 23284982
references.citation: Mol Cancer Res. 2012 Dec;10(12):1597-606
references.pmid: 23071104
references.citation: Lung Cancer. 2005 Sep;49(3):363-70
references.pmid: 15923058
references.citation: Anticancer Drugs. 2010 Jul;21(6):591-9
references.pmid: 20436341
references.citation: Cancer Res. 2004 Jun 1;64(11):3761-6
references.pmid: 15172981
references.citation: Expert Opin Biol Ther. 2012 Sep;12(9):1221-39
references.pmid: 22731874
references.citation: J Clin Oncol. 2005 May 1;23(13):3125-37
references.pmid: 15860872
references.citation: PLoS One. 2008;3(11):e3695
references.pmid: 19002265
references.citation: Cancer Res. 2007 May 1;67(9):4425-33
references.pmid: 17483357
references.citation: World J Gastroenterol. 2011 Sep 7;17(33):3810-7
references.pmid: 21987623
references.citation: Cancer Cell. 2010 Dec 14;18(6):606-18
references.pmid: 21156284
references.citation: Clin Cancer Res. 2002 Feb;8(2):555-65
references.pmid: 11839677
references.citation: J Biol Chem. 2012 Feb 3;287(6):4148-56
references.pmid: 22157765
references.citation: Lung Cancer. 2006 May;52(2):155-63
references.pmid: 16569462
references.citation: Lung Cancer. 2001 Feb-Mar;31(2-3):277-84
references.pmid: 11165408
references.citation: PLoS One. 2012;7(6):e40021
references.pmid: 22768203
references.citation: Pancreas. 2012 Jan;41(1):107-13
references.pmid: 21926937
references.citation: Cancer Sci. 2013 Oct;104(10):1303-8
references.pmid: 23822562
references.citation: Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92
references.pmid: 22399498
references.citation: J Clin Oncol. 2000 Jan;18(1):122-30
references.pmid: 10623702
references.citation: J Pharmacol Exp Ther. 2010 Dec;335(3):830-40
references.pmid: 20855443
references.citation: J Clin Oncol. 1999 Jan;17(1):12-8
references.pmid: 10458212
references.citation: Lung Cancer. 2000 Feb;27(2):75-80
references.pmid: 10688490
references.citation: J Natl Cancer Inst. 2003 Mar 5;95(5):362-72
references.pmid: 12618501
references.citation: Haematologica. 2013 Mar;98(3):414-9
references.pmid: 22983574
references.citation: Mol Cancer Ther. 2006 Jul;5(7):1800-6
references.pmid: 16891466
references.citation: Mol Cancer. 2010 May 28;9:130
references.pmid: 20509890
references.citation: Head Neck. 2011 Jun;33(6):786-91
references.pmid: 21560177
references.citation: Int J Cancer. 2014 Jan 1;134(1):43-54
references.pmid: 23784558
references.citation: Cancer Lett. 2013 Aug 9;336(1):231-9
references.pmid: 23673211
references.citation: PLoS One. 2012;7(4):e34994
references.pmid: 22514698
references.citation: PLoS One. 2010 Feb 15;5(2):e9219
references.pmid: 20169152
references.citation: Oncogene. 2009 Jun 11;28(23):2245-56
references.pmid: 19421142
references.citation: Anticancer Res. 2010 Oct;30(10):3919-25
references.pmid: 21036703
references.citation: Cancer Chemother Pharmacol. 2012 Jan;69(1):145-54
references.pmid: 21630085
references.citation: Blood. 2013 Mar 7;121(10):1824-38
references.pmid: 23299311
references.citation: Nat Med. 2012 Jun;18(6):892-901
references.pmid: 22610277
references.citation: Pharmacogenomics. 2009 Jan;10(1):69-80
references.pmid: 19102717
references.citation: Nature. 2005 Apr 14;434(7035):843-50
references.pmid: 15829953
references.citation: Oncol Rep. 2012 Jan;27(1):250-7
references.pmid: 21947305
references.citation: Carcinogenesis. 2012 Oct;33(10):1863-70
references.pmid: 22791817
references.citation: Mol Cancer Ther. 2009 May;8(5):1055-66
references.pmid: 19435871
references.citation: Int J Oncol. 2012 May;40(5):1581-9
references.pmid: 22266985
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):3094-101
references.pmid: 15837765